| Project/Area Number |
19K08931
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 54030:Infectious disease medicine-related
|
|---|
| Research Institution | Ehime University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
安川 正貴 愛媛県立医療技術大学, 保健科学部, 教授 (60127917)
|
|---|
| Project Period (FY) |
2019-04-01 – 2022-03-31
|
| Project Status |
Completed (Fiscal Year 2021)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2021: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2020: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | SFTS / 異型リンパ球 / ファビピラビル |
|---|
| Outline of Research at the Start |
重症熱性血小板減少症候群（Severe fever with thrombocytopenia syndrome; SFTS）は2011年に中国で初めて報告された新興感染症である。我が国でも2013年に初めて患者が確認され、致死率が10～30％と極めて高い。有効な治療法が確立されておらず、病態解明と治療法の確立は喫緊の課題である。本研究の目的は臨床像の病態解明により予後改善を目指すことである。
|
| Outline of Final Research Achievements |
During the study period, eight patients with severe febrile thrombocytopenia syndrome (SFTS) were delivered in Ehime prefecture, of which 3 (2 severe and 1 mild) were admitted to our hospital. Atypical lymphocytes were found in peripheral blood, and flow cytometric analysis showed that B cells were significant in severely ill patients, while T cells were significant in mildly ill patients. From April to December 2016 and from September 2017 to May 2018, favipiravir was administered as a new antiviral drug for SFTS for 7 to 14 days in a doctor-led clinical trial mainly at medical institutions in western Japan. The analysis was performed in our hospital. Twenty-three were enrolled in this study, 19 survived and 4 died (mortality rate 17.4%). Only previously reported adverse events were found, and no new adverse events were observed.
|
| Academic Significance and Societal Importance of the Research Achievements |
SFTS患者の末梢血を用いた解析からは、異型リンパ球がT細胞有意（通常のウイルス感染症と同様の免疫反応）であれば軽症であり、B細胞有意であれば重症の病態である可能性が示唆された。これらの所見は今後の診断および治療の発展に寄与する知見と思われる。医師主導型臨床試験で得られたファビピラビルの有効性と安全性についての解析は、現在、抗ウイルス薬が存在しないSFTSにおいて、治療薬として有効性が期待される結果であり、実臨床で使用できるポテンシャルが高い薬剤であることが示唆された。
|
